By Yasmeen Abutaleb and Jeff Mason WASHINGTON (Reuters) – U.S. President Donald Trump moved to undermine Obamacare dramatically late on Thursday by cutting off subsidies to health insurance companies for low-income patients, sparking threats of legal action and concern of chaos in insurance markets. The decision is the most dramatic action Trump has taken yet […]
FDA panel votes in favor of Spark’s blindness gene therapy
(Reuters) – Spark Therapeutics Inc’s experimental gene therapy for a rare form of blindness improves vision and should be approved, advisers to the Food and Drug Administration concluded on Thursday, paving the way for the first U.S. gene therapy for an inherited disease.
The panel voted unanimously in favor of the treatment, Luxturna, which is designed to treat inherited retinal diseases caused by defects in a gene known as RPE65, which tells cells to produce an enzyme critical to normal vision.
The FDA is not obliged to follow the recommendations of its advisers but typically does. Michael Yee, an analyst at Jefferies, said in a recent research report that approval of the therapy would “thematically mark a watershed moment for the entire field.”
The panel’s vote followed scientific presentations from Spark and the FDA and testimonies from patients who described the impact of the therapy, such as allowing them for the first time to see the moon and stars, go out with friends at night, and see food on their plate.
Retinal disease caused by defects to the RPE gene affect between 1,000 and 2,000 people in the United States. Roughly half of those become legally blind by the age of 16 and all are legally blind by the age of 34. Most progress to complete blindness.
Legal blindness refers to people whose vision is 20/200 or less. A person with normal vision can see an object 200 feet away. A legally blind person must stand 20 feet in front of it. People who are completely blind cannot see any light or shapes.
Clinical trial results showed 93 percent of participants experienced some improvement in their functional vision as measured by their ability to navigate obstacles in poor light.
(Reporting by Toni Clarke in Washington; Editing by Steve Orlofsky and Diane craft)
- Trump nails Obamacare with decision to cut off billions in subsidies
Oct 13, 2017
- Trump strikes blow at Iran nuclear deal in major U.S. policy shift
Oct 13, 2017
- Russia probe special counsel interviews ex-Trump chief of staff Priebus
Oct 13, 2017
- NFL to tackle protests as Trump decries ‘disrespectful’ players
Oct 16, 2017
- Senate health care deal in doubt as Trump says he’s opposed
Oct 18, 2017
Editorial CartoonsView More »
Tue, Oct 10, 2017